Heron Therapeutics stock fell 2.33 percent on October 2

Published on 10/05/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Heron Therapeutics stock stood at USD 0.35 on Nasdaq on October 2, 2026. Q2 revenue reached USD 37.67 million versus USD 42.19 million expected.

HRTX, US4277461020, Illustration mit AI erstellt.

Heron Therapeutics stock (ISIN US4277461020) was last at USD 0.35 on Nasdaq on October 2, 2026, down 2.33 percent on the session. The company is expanding its commercial portfolio through a September 23 license agreement with Long Grove Pharmaceuticals and Capstone, according to StockTitan.

Exclusive rights add portfolio breadth

The agreement gives Heron an exclusive, sublicensable license to import, distribute, sell and market certain products in the United States, plus a non-exclusive worldwide manufacturing license for U.S. sales, StockTitan reports.

The initial term runs for 10 years after the first commercial sale, with automatic two-year renewals. Heron must make regulatory milestone payments, sales-based milestone payments and royalty payments, while the complete agreement is slated for inclusion in the quarterly report for the period ending September 30, 2026.

Q2 revenue missed expectations

Heron's second-quarter 2026 revenue was USD 37.67 million, compared with USD 42.19 million expected, while the company reported a quarterly loss of USD 0.03 per share, according to MarketBeat. The revenue gap was USD 4.52 million, making commercial execution the central measure for the next quarterly update.

Heron describes itself as a commercial-stage biotechnology company focused on acute care and oncology. Its marketed portfolio includes ZYNRELEF for postsurgical pain and APONVIE for preventing postoperative nausea and vomiting, according to MarketBeat.

Consensus target towers over the quote

MarketBeat reports a consensus Hold rating from five analysts, split between one Buy, three Hold and one Sell recommendation. The average 12-month target is USD 2.00, which places the USD 0.35 share price 82.5 percent below the consensus target.

That gap sits beside a wide 52-week range of USD 0.26 to USD 1.58. Heron Therapeutics had a market capitalization of USD 65.8 million and trading volume of 4,078,353 shares on October 2, 2026, keeping the stock firmly in micro-cap territory.

Heron Therapeutics stock stays below USD 1

Heron Therapeutics stock was last at USD 0.35 on Nasdaq on October 2, 2026 at 4:00 p.m. ET. The license deal offers a concrete portfolio expansion, while the Q2 revenue miss and the distance between the market price and analyst consensus leave execution as the key valuation test.